Skip to main content

Table 2 Relation between some clinical or tumor characteristics and tumor PET-derived image parameters in 143 patients with ER+/HER2- breast cancer

From: 18FDG-PET/CT for predicting the outcome in ER+/HER2- breast cancer patients: comparison of clinicopathological parameters and PET image-derived indices including tumor texture analysis

  Age Tumora Lymph nodesa Histology Grade PR expression
≤40 >40 ≤50 >50 T2 T3 N0 N+ IDC ILC 1–2 3 Neg Pos
No. patients 27 116 74 69 53 56 58 85 129 7 98 42 55 88
SUVmax med 5.4 6.8 6.5 6.6 5.2 5.9 6.1 6.6 6.8 4.8 5.4 7.9 7.2 5.7
P 0.31 0.63 0.56 0.79 0.43 <0.01 0.06
SUVmean med 3.1 3.6 3.4 3.6 2.9 3.3 3.5 3.5 3.6 3.0 3.1 4.2 4.0 3.2
P 0.36 0.67 0.59 0.77 0.31 <0.01 0.06
SUVpeak med 4.3 5.3 5.1 5.1 4.1 4.9 4.9 5.1 5.2 4.4 4.4 6.4 5.7 4.5
P 0.32 0.60 0.44 0.81 0.63 <0.01 0.05b
MATV med 10.1 11.2 11.0 9.6 6.7 10.8 9.2 11.3 10.1 32.5 10.9 10.4 13.9 9.1
P 0.33 0.86 <0.01 0.24 0.02b 0.83 0.03b
TLG med 27.2 39.0 33.5 35.2 20.1 33.5 32.7 40.5 32.8 74.6 32.1 44.8 46.3 28.2
P 0.22 0.86 <0.01 0.41 0.16 0.05b 0.01b
H med 0.12 0.12 0.12 0.12 0.11 0.12 0.12 0.12 0.12 0.14 0.12 0.12 0.13 0.12
P 0.81 0.87 0.02 0.10 0.09 0.73 0.12
E med 3.5 3.8 3.7 3.6 3.2 3.7 3.5 3.8 3.6 4.8 3.7 3.7 4.0 3.5
P 0.18 0.97 <0.01 0.25 0.02b 0.70 0.02b
  1. P value for comparison of median values with the Wilcoxon rank sum test. Bold numerals correspond to P values keeping statistically significant after multiple corrections from Benjamini-Hochberg
  2. PET positron emission tomography, ER+/HER2- estrogen receptor-positive/human epidermal growth factor receptor 2-negative, PR progesterone receptor, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, SUV standardized uptake value, MATV metabolically active tumor volume, TLG total lesion glycolysis, H homogeneity, E entropy
  3. aClinical classification according to the seventh edition of the AJCC Cancer Staging Manual
  4. bNot significant after correction for multiple testing